- Home
- OPY vs ALEC Comparison
OPY vs ALEC Comparison
Compare OPY & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- ALEC
- Stock Information
- Founded
- OPY 1881
- ALEC 2013
- Country
- OPY United States
- ALEC United States
- Employees
- OPY N/A
- ALEC N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPY Finance
- ALEC Health Care
- Exchange
- OPY Nasdaq
- ALEC Nasdaq
- Market Cap
- OPY 521.3M
- ALEC 487.7M
- IPO Year
- OPY N/A
- ALEC 2019
- Fundamental
- Price
- OPY $48.81
- ALEC $4.70
- Analyst Decision
- OPY
- ALEC Strong Buy
- Analyst Count
- OPY 0
- ALEC 6
- Target Price
- OPY N/A
- ALEC $17.75
- AVG Volume (30 Days)
- OPY 21.4K
- ALEC 465.2K
- Earning Date
- OPY 11-01-2024
- ALEC 11-05-2024
- Dividend Yield
- OPY 1.47%
- ALEC N/A
- EPS Growth
- OPY 103.21
- ALEC N/A
- EPS
- OPY 5.47
- ALEC N/A
- Revenue
- OPY $1,224,117,000.00
- ALEC $55,275,000.00
- Revenue This Year
- OPY N/A
- ALEC N/A
- Revenue Next Year
- OPY N/A
- ALEC $96.01
- P/E Ratio
- OPY $8.97
- ALEC N/A
- Revenue Growth
- OPY 3.10
- ALEC N/A
- 52 Week Low
- OPY $32.82
- ALEC $3.66
- 52 Week High
- OPY $58.35
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- OPY 44.91
- ALEC 45.29
- Support Level
- OPY $47.89
- ALEC $4.51
- Resistance Level
- OPY $50.93
- ALEC $5.35
- Average True Range (ATR)
- OPY 0.91
- ALEC 0.31
- MACD
- OPY 0.11
- ALEC 0.02
- Stochastic Oscillator
- OPY 35.31
- ALEC 42.73
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has three segments: private client, asset management, and capital markets. The Private Client segment, commissions and a proportionate amount of fee income earned on assets under management ("AUM"), net interest earnings on client margin loans and cash balances, fees from money market funds, and custodian fees. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.